RYGANVI Trademark

Trademark Overview

On Friday, July 9, 2021, a trademark application was filed for RYGANVI with the United States Patent and Trademark Office. The USPTO has given the RYGANVI trademark a serial number of 90819941. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, May 29, 2024. This trademark is owned by Genentech, Inc.. The RYGANVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in neurological disorders including Alzheimers
ryganvi

General Information

Serial Number90819941
Word MarkRYGANVI
Filing DateFriday, July 9, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, May 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 12, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in neurological disorders including Alzheimers

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 16, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenentech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameGenentech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Tuesday, July 13, 2021NEW APPLICATION ENTERED
Thursday, September 16, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 7, 2022ASSIGNED TO EXAMINER
Wednesday, March 9, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 9, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, March 9, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 9, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, April 12, 2022PUBLISHED FOR OPPOSITION
Wednesday, March 9, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 12, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 7, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, October 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 19, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 19, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, October 26, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 26, 2022SOU EXTENSION 1 FILED
Wednesday, October 26, 2022SOU EXTENSION 1 GRANTED
Wednesday, April 19, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, April 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, November 20, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 20, 2023SOU EXTENSION 3 FILED
Monday, November 20, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 29, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, May 29, 2024SOU EXTENSION 4 GRANTED
Wednesday, May 29, 2024SOU EXTENSION 4 FILED
Thursday, May 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 16, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 16, 2023SOU EXTENSION 2 FILED
Tuesday, May 16, 2023SOU EXTENSION 2 GRANTED

Related Keywords

ryganvi including alzheimers disorders neurological preparations pharmaceutical